Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aytu BioPharma Q4 EPS $(2.92) Misses $(0.04) Estimate, Sales $15.135M Miss $17.922M Estimate

Author: Benzinga Newsdesk | September 23, 2025 03:06pm
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(2.92) per share which missed the analyst consensus estimate of $(0.04) by 7791.89 percent. This is a 256.1 percent decrease over losses of $(0.82) per share from the same period last year. The company reported quarterly sales of $15.135 million which missed the analyst consensus estimate of $17.922 million by 15.55 percent. This is a 3.71 percent increase over sales of $14.593 million the same period last year.

Posted In: AYTU


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist